Jw (cayman) Therapeutics Co. Ltd. · HKEX:2126
Jw (cayman) Therapeutics — JW Therapeutics — FY2024 Earnings Presentation
13 slides from Jw (cayman) Therapeutics's earnings presentation, 2025
Slide 1: JW Therapeutics 2024 Annual Results Presentation
JW Therapeutics (2126.HK) 2024 Annual Results Presentation 1
Slide 2: Disclaimer 免责声明
Disclaimer 免责声明 This presentation may contain forward-looking, confidential and/or proprietary information including without limitation to JW Therapeutics’ manufacturing process, pipeline, business development and third party collaboration, etc, which are provided on as-is basis, and/or based on man
Slide 3: JW Therapeutics 2024 Business Review
JW Therapeutics 2024 Business Review R＆D Progress ◼ Carteyva® Hematology Programs made significant progress in 2024，including: 1) 2L LBCL patient recruitment was ahead of plan and enrollment was completed in Q4 2024. The NMPA had granted Breakthrough Therapy Designation to Carteyva® for this indicat
Slide 4: Hematology and Autoimmune Pipeline: Hematologic Malignancies
Our Hematology and Autoimmune Pipeline: Expanding Indications to Benefit Patients Hematologic Malignancies and Autoimmune Diseases Pivotal / Product Target Indication Commercial Rights Pre-clinical Phase I Phase II/III NDA Marketed Partner Mainland China, Hong Kong, 3L LBCL Macau* Mainland China, Ho
Slide 5: Carteyva: Advancing in CD19+ Indications: r/r MCL
Carteyva®: Advancing in CD19+ Indications: r/r MCL Carteyva® is the first commercial CAR-T cell Carteyva® demonstrate excellent efficiency and safety product for the treatment of r/r MCL in China profile in clinical trails • MCL is a heterogeneous B cell non-Hodgkin lymphoma 59 high risk patients wh
Slide 6: Carteyva: Advancing in CD19+ Indications: 2L transplant-ineligible r/r LBCL
Carteyva®: Advancing in CD19+ Indications: 2L transplant- ineligible r/r LBCL Carteyva® is expected to become the first CAR-T cell Carteyva® demonstrate excellent efficiency and safety product for the treatment of 2L transplant-ineligible profile in clinical trails patients with r/r LBCL • Large B-c
Slide 7: First in Human Study of Relma-cel in SLE
First in Human Study of Relma-cel in SLE First in human study dose escalation completed and in follow up stage, promising efficacy and tolerable safety profile observed Target Population Patients with moderate-to-severe, refractory/relapse Systemic Lupus Erythematosus (SLE) SLE Classification: diagn
Slide 8: Very Promising Efficacy Signal Observed in the FIH Study
Very Promising Efficacy Signal Observed in the FIH Study • Three patients were all female, aged 21-36, Overall trend: • CAR-T cell expansion with multi-organ involvement and prior reached a Cmax of 19.72 • Autoantibodies: ds-DNA cell/ul, peaking 8-22 days treatment with high-dose steroids and decrea
Slide 9: Our Pipeline Beyond Heme: Expanding Solid Tumor Indications
Our Pipeline Beyond Heme: Expanding Solid Tumor Indications High Incidence Diseases in China: HCC, Lung Cancer and More Pivotal / Product Target Indication Commercial Rights Pre-clinical Phase I Phase II/III NDA Marketed Partner Mainland China, Hong Kong, JWATM204 1 GPC3 HCC Macau, Taiwan , and memb
Slide 10: JWTCR001: MAGE-A4 Autologous TCR-T in Multiple Solid Tumors
JWTCR001: MAGE-A4 Autologous TCR-T in Multiple Solid Tumors JW’s TCR-T Product Candidate Employing Novel Technology & Successful Manufacturing Processes TCR-T has Solid Proof of Concept Through Clinical Trials Novel Technology Licensed from 2seventy Bio Phase 2: NY-ESO-1/HLA-A2(GSK) & MAGE-A4/HLA-A2
Slide 11: In-house Generated New Pipeline with Global Reach
In-house Generated New Pipeline with Global Reach New Autologous CAR Pipeline Autologous Therapies • Proven approach • Leveraging on JW infrastructure and experience Global Next-Gen New Pipeline Value Drivers Armored Commercial Manufacturing • Targeting unmet needs in China with potential global Rig
Slide 12: 2024 Commercialization Review
2024 Commercialization Review CAR-T is an Emerging and Disruptive Therapy JW’s Commercial Progress in 2024 CAR-T is a therapy with unprecedented outcomes Sales Maintained with Dynamic Market Changes in hematological malignancies Revenue Achieved by Sales of Carteyva® (RMB million) • In RELIANCE stud
Slide 13: Financial Update
Financial Update Revenue Gross Margin (RMB million) (RMB million) 173.9 88.2 158.2 77.3 GM% 50.7% 2023 2024 2023年 2024年 Operation Expenses Cash Reserve (RMB million) 666.8 (RMB million) 140.0 543.5 113.2 120.1 140.4 869.0 757.4 413.6 283.0 2023 2024 June 30, 2024 Dec 31, 2024 R＆D Expenses Selling Ex